Noxopharm Ltd. · ASX:NOX
Noxopharm — Shareholder Meeting (November 2021)
38 slides from Noxopharm's shareholder meeting presentation, Nov 17, 2021
Slide 1: Noxopharm 2021 AGM Corporate Presentation
For personal use only Noxopharm Limited (ASX:NOX) | ASX Announcement | 17 November 2021 Noxopharm 2021 AGM Corporate Presentation • Scientific research this year continues to validate potential major role for Veyonda as standard of care cancer therapy • Patent protection building to underpin the com
Slide 2: Forward Looking Statements
Investor, Corporate & Media enquiries: Company Secretary: Prue Kelly David Franks For personal use only M: 0459 022 445 T: +61 2 8072 1400 E: info@noxopharm.com E: David.Franks@automicgroup.com.au Forward Looking Statements This announcement may contain forward-looking statements. You can identify t
Slide 3: Noxopharm Limited AGM 2021
For personal use only Noxopharm Limited AGM 2021 NOXOPHARM (ASX:NOX)
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for secu
Slide 5: CEO Dr Graham Kelly
For personal use only CEO Corporate Update Dr Graham Kelly CEO and MD
Slide 6: 2021 AGM: synthetic isoflavonoid platform
2021 AGM For personal use only A future based on a proprietary synthetic isoflavonoid platform providing The Company has a unique family of drugs: reached a major • with multiple targets of action milestone in its development • an ability to distinguish between normal and abnormal functions a new ge
Slide 7: Key business opportunities
4 key business opportunities For personal use only Veyonda®️ Cancer Research Veyonda®️ Pipeline Chronic inflammatory Cancer treatment Cancer growth Septic shock diseases/autoimmune enhancement factor inhibitors diseases 5 © Noxopharm 2021
Slide 8: Oncology - Veyonda
Oncology - Veyonda® For personal use only Completing the package to increase the value and attraction of Veyonda® as an acquisition target Orphan Drug Full range of Patent Mechanisms of designations clinical portfolio action Market opportunities Use claims Drug category exclusivity Value creation Pr
Slide 9: Oncology - Pipeline
Oncology - Pipeline For personal use only A pipeline of 3 exciting new anti-cancer drugs with novel actions Drug 1: Drug 2: Drug 3: Glial brain cancers Pancreatic cancer Multiple cancer types (GBM, DIPG) G-protein coupled receptor inhibitors Second generation Veyonda Targeting highly aggressive canc
Slide 10: Sepsis - Veyonda
Sepsis - Veyonda® For personal use only Anti-inflammatory action blocking cytokine storm and sepsis Pre-clinical programs Clinical program Mouse influenza virus model testing: • Lung inflammation Awaiting notification of acceptance • Viral replication into a global adaptive study Veyonda®️ Direct an
Slide 11: Inflammation - Pharmorage
Inflammation - Pharmorage For personal use only Development of anti-inflammatory drugs based on two technology platforms Synthetic Isoflavonoids RNA technology Pharm-ISO Pharm-RNA Novel family of inhibitors of TBK1 In vivo testing of RNA drug(s) as and certain other inflammatory treatments of autoim
Slide 12: Summary
Summary For personal use only • A unique synthetic isoflavonoid technology platform offering the ability to meet two needs of human degenerative disease - multiple errors and ability of the drugs to distinguish healthy from unhealthy cells • A strategy to establish the value of the oncology business
Slide 13: Company Key Metrics
Company Key Metrics For personal use only Number of Shares 292.2 million Board Shareholding 14.8% Share Price (12/11/21) 48 cents Market Cap (12/11/21) $142 million Cash position (30/9/21) $23.6 million 11 © Noxopharm 2021
Slide 14: Clinical Portfolio Overview
For personal use only Clinical Portfolio Overview Dr Gisela Mautner, CMO MD-PhD (TU Munich-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia), MAICD
Slide 15: Clinical Portfolio – Key Considerations
Clinical Portfolio – Key Considerations For personal use only Strategic direction is underpinned by the following considerations: • Data: a sound rationale based on preclinical data • Diversity: a diverse portfolio with a clear focus on progressing the research • Risk Management: a robust risk manag
Slide 16: Taking a Portfolio Approach
Taking a Portfolio Approach For personal use only Cancer types Indications Disease state: Oligometastatic nmHSPC mHSPC Prostate nmCRPC mCRPC Breast Combination with: Radiation LuPSMA Lung Chemo XYZ Other drugs … Sarcoma … 14 © Noxopharm 2021
Slide 17: Taking a Cost-Effective Approach
Taking a Cost-Effective Approach For personal use only $$$ $ Phase 1 Phase 2 Phase 3 Expenditure 15 © Noxopharm 2021
Slide 18: Veyonda Clinical Development Portfolio
Veyonda® Clinical Development Portfolio For personal use only Program Combination Indication Phase 1 Phase 2 Veyonda + DARRT Prostate Ca DARRT-1 Completed DARRT-2 Active EBRT Veyonda + Multiple IONIC Active IONIC nivolumab Tumours Veyonda + LuPIN 177LuPSMA-617 Prostate Ca LuPIN Completed Multiple CE
Slide 19: DARRT-2 Trial
DARRT-2 Trial For personal use only • IND received from FDA • Two clinical sites in the USA are fully contracted and received Ethics approval • More sites are starting up in coming months in AUS and Europe • Active recruitment of patients • Study is in 2 parts: • Dose escalation: 1200 mg to 2400 mg;
Slide 20: IONIC Trial
IONIC Trial For personal use only • Investigator initiated study • Actively recruiting • First 2 patients enrolled • First safety report shortly (after 3 patients have completed 1 cycle of Veyonda + nivolumab) & Nivolumab owned by BMS Veyonda 18 © Noxopharm 2021
Slide 21: CEP-2 Trial
CEP-2 Trial For personal use only • IND from FDA received • Trial will be conducted in the USA due to strong interest • Contract negotiations with clinical sites are ongoing • Ethics approvals for sites are expected shortly MRI showing sarcoma of the knee 19 © Noxopharm 2021 (Photo: semnic/Getty Ima
Slide 22: LuPIN Trial
LuPIN Trial For personal use only • Promising results have been published in peer-reviewed medical journals: • Any PSA reduction in 86% of patients • PSA fall of >50% in 61% of patients • Median Overall Survival of 19.7 months • Discussions regarding potential trial at a European site are currently
Slide 23: NOXCOVID Trial
NOXCOVID Trial For personal use only • Results of NOXCOVID-study were very encouraging • Negotiations with other COVID research teams are ongoing • We will not proceed without non-dilutive funding Change in Mean News2 Score During Treatment 6 Veyonda Dosed for 14 days 5 4 NEWS2 Score 3 2 1 0 0 5 10
Slide 24: Clinical Portfolio - Key Takeaways
Clinical Portfolio - Key Takeaways For personal use only We have 3 exciting ongoing studies DARRT-2 • Our biggest study to date • Building on DARRT-1 with a more intense treatment • Prestigious hospitals are participating IONIC • Our proof-of-concept study with a unique combination (Opdivo, BMS) • M
Slide 25: For personal use only
For personal use only 23 © Noxopharm 2021
Slide 26: Introduction to Pharmorage
For personal use only Introduction to Pharmorage Dr Olivier Laczka Group CSO © Noxopharm 2021 24
Slide 27: The genesis
The genesis For personal use only 2008 2015 2018 2019 2020 2021 STING protein is STING pathway is Big pharma enter the Big pharma start IDX is confirmed as a strong Pre-clinical data discovered confirmed as a major race to develop STING realizing that STING antagonist of the STING supports IDX is (S
Slide 28: The HIMR In-licenced RNA technology platform
The HIMR In-licenced RNA technology platform For personal use only The Pharm-RNA platform 26 © Noxopharm 2021
Slide 29: The Pharmorage concept
The Pharmorage concept For personal use only Inflammation, chronic inflammation, autoimmune diseases: Where do we position ourselves? 27 © Noxopharm 2021 Scope of indications and market potential are extensive…
Slide 30: The opportunity: a large market in expansion
The opportunity: a large market in expansion For personal use only The growing autoimmune and chronic inflammation market USD$ USD$ 28 © Noxopharm 2021
Slide 31: The added opportunity: the mRNA therapeutics sector
The added opportunity: the mRNA therapeutics sector For personal use only Pharmorage does NOT focus on developing mRNA therapeutics (drugs and Vaccines), but its synthetic RNA platform and pipeline is tailored to support the future development of these technologies by other companies The Pharm-RNA p
Slide 32: The added opportunity: the mRNA therapeutics sector
The added opportunity: the mRNA therapeutics sector For personal use only The raise of the Oligonucleotide therapeutics era, a launch pad for our in-licensed Pharm-RNA platform More than one half (54%) of current mRNA pipeline projects are sponsored by public companies. 30 © Noxopharm 2021
Slide 33: The added opportunity: oligonucleotide therapeutics
The added opportunity: oligonucleotide therapeutics For personal use only The raise of the Oligonucleotide therapeutics era, a launch pad for our in-licensed Pharm-RNA platform Oligo therapeutics targeting hypercholesterolemia acquired for USD$9B by Novartis – recently approved by EU. It only needs
Slide 34: Our technologies and assets
Our technologies and assets For personal use only Two platforms with 3 preclinically advanced drug candidates Technology platforms Most advanced drug candidates Application areas Small molecules (Pharm-ISO) • TBK1 Inhibitor lead compound selection (Pharm-ISO-1) Infection-driven inflammation (From No
Slide 35: Our technology and assets
Our technology and assets For personal use only Two platforms each targeting different level of the inflammation cascade Acts on specific inflammation triggers (HIMR) Blunts multiple inflammation signals (NOX) 33 © Noxopharm 2021
Slide 36: A couple of practical examples
A couple of practical examples For personal use only An infection with an RNA virus (such as SARS-COV2), An acquired, mRNA-stimulated, or genetic autoimmune with associated tissue damage releasing self-DNA inflammation disease due to an overactivated inflammation TLR7 receptor Pharm-ISO (NOX) Pharm-
Slide 37: Technical Glossary
Technical Glossary For personal use only mRNA: messengerRNA (mRNA) is a single-stranded RNA molecule that is TBK1: (TANK-binding kinase 1) is an enzyme with kinase activity. Specifically, it is complementary to one of the DNA strands of a gene. The mRNA is an RNA version of a serine / threonine prot
Slide 38: NOXOPHARM
For personal use only NOXOPHARM (ASX:NOX)